Johnson & Johnson reported strong Q3 results, beating analyst estimates for both earnings and sales, and subsequently raised its full-year guidance. Despite this positive performance, two prominent analysts, RBC Capital and Wells Fargo, lowered their price targets for JNJ stock, indicating a potential re-evaluation of future growth prospects or valuation multiples.
Johnson & Johnson (JNJ) delivered a robust third quarter, exceeding analyst expectations for both top and bottom lines and subsequently increasing its full-year financial outlook. This would typically be a strong positive catalyst for the stock. However, the filing highlights that two major analysts, RBC Capital and Wells Fargo, chose to *lower* their price targets for JNJ following these results. This divergence suggests that while current performance is strong, analysts may be factoring in other considerations such as broader market conditions, competitive landscape, or a re-evaluation of long-term growth potential that could temper future upside. For traders, this creates a nuanced situation: strong fundamentals versus a potential cooling of analyst sentiment, which could lead to short-term volatility or a cap on immediate price appreciation despite positive news.